Biotech Showcase™ 2019: VBC III targets European therapeutic, medtech & digital health opportunities

https://ebdgroup.knect365.com/biotech... Having raised EUR 65 million in a first close in May 2017, Versalius BioCapital expects to close its third fund two years on at some EUR 120 million. Speaking during Biotech Showcase 2019, Marc Lohrmann, managing partner of VBC III, explains how the new fund is looking to invest in maturing European companies across the whole medical life sciences landscape from therapeutics to diagnostics, medical devices and digital health products.